Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02860039 · ClinicalTrials.gov registry record · Phase 2
High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant
A Phase 2 study, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 170
- Enrollment target
NCT02860039 is a Phase 2 study that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 170 participants.
The verdict
NCT02860039, a Phase 2 study, has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 170 participants
- Enrollment target
Study Summary
This phase II randomized trial studies how well high dose flu vaccine works in treating children who have undergone done stem cell transplant. Higher dose flu vaccine may build a better immune response and may provide better protection against the flu than the standard vaccine.
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Trivalent Influenza Vaccine
- BIOLOGICAL Quadrivalent Influenza Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2016-09 |
| Est. Completion | 2024-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02860039
The ClinicalTrials.gov registry entry for NCT02860039 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02860039 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02860039 about?
NCT02860039 is a clinical study titled "High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant". This phase II randomized trial studies how well high dose flu vaccine works in treating children who have undergone done stem cell transplant. Higher dose flu vaccine may build a better immune response and may provide better protection against the flu than the standard vaccine.
What is the current status of trial NCT02860039?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2016-09. Estimated completion is 2024-09.
What interventions are being tested in trial NCT02860039?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Trivalent Influenza Vaccine (BIOLOGICAL), Quadrivalent Influenza Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02860039?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.